Novacap, a global player in the pharmaceutical synthesis and specialty ingredients, with a broad portfolio of products and services and a wide range of technologies, announced that it will combine its contract development and manufacturing organization (CDMO) subsidiaries, PCI Synthesis, PCAS, Uetikon and Proteus, into a new entity to be known as SEQENS.
The name change will be rolled out during Q1 2019 at each of SEQENS’ 24 manufacturing plants and 3 R&D centers in Europe, North America and Asia. By consolidating its service offerings, SEQENS can better serve its customers with global access to its 3200 employees, including more than 300 scientists, engineers and experts, and ensure that products are successfully transferred into production. SEQENS’ name refers naturally to the company’s core synthesis activities, combined with the sequencing of molecules, competencies and technologies to take science to the next level.
In the pharmaceutical industry, SEQENS supports its customers for the development, scale-up and manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products.
Novacap is an international group that produces and distributes APIs and essential chemicals products that are used in everyday applications such as aspirin, paracetamol, other APIs, salicylic acid, para-aminophenol, soda ash, sodium bicarbonate, phenol, oxygenated solvents and ferric chloride. The group is an industry leader across a wide range of products. It benefits from a solid European platform complemented by a well-established presence in Asia and an increasing footprint in North America.